我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

S100B在大鼠颈总动脉损伤后新生内膜中的表达及意义

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2016年第6期
页码:
660-665
栏目:
基础研究
出版日期:
2016-07-05

文章信息/Info

Title:
Clinical significance of S100B expression in rat carotid artery neointima after injury
作者:
杨 波1; 曹 腾1; 唐俊明2; 杨建业2; 张 蕾2; 吴 冰2; 王家宁2
（1.武汉大学人民医院心血管内科，湖北 武汉 430060；2.湖北医药学院附属人民医院临床医学研究所，湖北 十堰 442000）
Author(s):
YANG Bo1;  CAO Teng1;  TANG Jun-ming2;  YANG Jian-ye2;  Zhang Lei2;  WU Bing2;  WANG Jia-ning2
(1.Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China；
2.Institute of Clinical Medicine, Renmin Hospital of Hubei University of Medicine, Shiyan 442000, Hubei, China)
关键词:
S100B; 球囊损伤;  新生内膜; 新生内膜增生; 颈总动脉
Keywords:
S100B;  balloon injury;  neointima;  neointimal hyperplasia;  carotid artery
分类号:
R543.5
DOI:
-
文献标识码:
A
摘要:
目的 探讨S100B在大鼠颈总动脉损伤后新生内膜中表达特征及其临床意义。方法 将体质量400~500 g SD大鼠，随机分为假手术组和颈总动脉球囊损伤模型组，于术后1、3、7、14和28 d取损伤的颈总动脉，40 g/L福尔马林固定过夜，切片行HE染色观察新生内膜形成情况，Western blot、qRT-PCR、免疫组化染色检测S100B的表达。检测干预因素对新生内膜影响时，将大鼠随机分为3组，即假手术组、Ad-GFP组、Ad-shS100B组，假手术组不做球囊拉伤，其余两组除球囊拉伤外分别给予200 μl Ad-GFP和Ad-shS100B。结果 颈总动脉损伤后，新生内膜增生随着时间的延长呈现出逐渐增加的趋势，且在14 d时达峰值（P<0.05），而内膜与中膜面积比值在28 d达到最大。qRT-PCR显示S100B-mRNA在颈总动脉损伤后呈现出第1天升高，第3、7天时有所下降，第14天时上升，而第28天又下降的动态趋势(P<0.05)。Western blot显示颈总动脉损伤后S100B表达逐渐增加，7 d时达到高峰，随后降低（P<0.05）。免疫组化结果显示增加的S100B蛋白主要存在于新生内膜中。给予Ad-shS100B干预后，新生内膜形成及S100B的表达明显受到抑制。结论 颈总动脉损伤后S100B的表达特征与新生内膜的形成有关。
Abstract:
AIM To explore the expression and clinical significance of S100B neointima of carotid artery after balloon injury. METHODSSprague Dawley (SD) rats (400-500) g were divided into control group and experimental group. The rat left common carotid artery injury model was established in experimental group using 2F Fogarty catheter. Carotid arteries were harvested for histomorphology and molecular markers assay on days 1, 3, 7, 14 and 28 after balloon injury. Hematoxylin and eosin staining was used to assess the changes of neointimal formation in the carotid artery and S100B expression was evaluated using Western blotting, qRT-PCR and immunohistochemical staining. Rats were randomly allocated into three groups to detect impact on neointimal information, namely, sham group without balloon injury, Ad-GFP group and Ad-shS100B group, respectively, experiencing 200 μl Ad-GFP, Ad-shS100B incubation and balloon injury. RESULTSAs the time of carotid arteries injury progressed, neointimal hyperplasia in carotid arteries revealed a gradual increasing trend, achieving peak at day 14 (P<0.05) and intima/media ratio reached a maximum at day 28. QRT-PCR revealed that S100B-mRNA expressions increased at day 1, declined at days 3 and 7, increased again at day 14 and decreased again at day 28 in carotid arteries after injury (P<0.05). Western blotting showed that S100B expressions increased from day 1 to day 7. After reaching a peak at day 7, the expressions gradually decreased at day 14 and day 28 (P<0.05). Immunohistochemical analysis localized S100B protein mainly in neointima layer of carotid arteries after injury, reaching a maximum at day 7 after injury (P<0.05). Administration with Ad-shS100B significantly reduced neointimal formation and S100B expression. CONCLUSIONThe characteristics of S100B expressions may be associated with neointimal formation in carotid arteries after injury.

参考文献/References

[1]Donato R.S100:a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles[J].Int J Biochem Cell Biol,2001,33(7):637-668.
[2]Marenholz I,Heizmann CW,Fritz G.S100 proteins in mouse and man:from evolution to function and pathology (including an update of the nomenclature)[J].Biochem Biophys Res Commun,2004,322(4):1111-1122.
[3]Donato R,Sorci G,Riuzzi F,et al.S100B’s double life:intracellular regulator and extracellular signal[J].Biochim Biophys Acta,2009,1793(6):1008-1022.
[4]Tsoporis JN,Overgaard CB,Izhar S,et al.S100B modulates the hemodynamic response to norepinephrine stimulation[J].Am J Hypertens,2009,22(10):1048-1053.
[5]Suzuki F,Kato K,Nakajima T.Hormonal regulation of adipose S-100 protein release[J].J Neurochem,1984,43(5):1336-1341.
[6]Donato R,Sorci G,Riuzzi F,et al.S100B's double life:intracellular regulator and extracellular signal[J].Biochim Biophys Acta,2009,1793(6):1008-1022.
[7]Leite MC,Galland F,de Souza DF,et al.Gap junction inhibitors modulate S100B secretion in astrocyte cultures and acute hippocampal slices[J].J Neurosci Res,2009,87(11):2439-2446.
[8]Nardin P,Tortorelli L,Quincozes-Santos A,et al.S100B secretion in acute brain slices:modulation by extracellular levels of Ca(2+) and K (+)[J].Neurochem Res,2009,34(9):1603-1611.
[9]Tsoporis JN,Marks A,Haddad A,et al.S100B expression modulates left ventricular remodeling after myocardial infarction in mice[J].Circulation,2005,111(5):598-606.
[10]Tsoporis JN,Marks A,Van Eldik LJ,et al.Regulation of the S100B gene by alpha 1-adrenergic stimulation in cardiac myocytes[J].Am J Physiol Heart Circ Physiol,2003,284(1):H193-H203.
[11]Zhou Z,Wang K,Penn MS,et al.Receptor for AGE(RAGE)mediates neointimal formation in response to arterial injury[J].Circulation,2003,107(17):2238-2243.
[12]Tulis DA.Rat Carotid Artery Balloon Injury Model[J].Methods Mol Med,2007,139:1-30.
[13]Reddy MA,Li SL,Sahar S,et al.Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells[J].Biol Chem,2006,281(19):13685-13693.
[14]Celikbilek A,Celikbilek M,Sabah S,et al.The Serum S100B Level as a Biomarker of Enteroglial Activation in Patients with Ulcerative Colitis[J].Int J Inflam,2014,2014:986525.
[15]Sen J,Belli A.S100B in neuropathologic states:the CRP of the brain[J].J Neurosci Res,2007,85(7):1373-1380.
[16]Dassan P,Keir G,Brown MM.Criteria for a clinically informative serum biomarker in acute ischaemic stroke:a review of S100B[J].Cerebrovasc Dis,2009,27(3):295-302.
[17]Beharier O,Kahn J,Shusterman E,et al.S100B-a potential biomarker for early detection of neonatal brain damage following asphyxia[J].J Matern Fetal Neonatal Med,2012,25(9):1523-1528.
[18]Seco M,Edelman JJ,Wilson MK,et al.Serum biomarkers of neurologic injury in cardiac operations[J].Ann Thorac Surg,2012,94(3):1026-1033.
[19]Tsoporis JN,Marks A,Haddad A,et al.S100B expression modulates left ventricular remodeling after myocardial infarction in mice[J].Circulation,2005,111(5):598-606.
[20]Parker TG,Marks A,Tsoporis JN.Induction of S100b in myocardium:an intrinsic inhibitor of cardiac hypertrophy[J].Can J Appl Physiol,1998,23(4):377-389.
[21]Hayakawa E,Yoshimoto T,Sekizawa N,et al.Overexpression of receptor for advanced glycation end products induces monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cell line[J].J Atheroscler Thromb,2012,19(1):13-22.
[22]Meng L,Park J,Cai Q,et al.Diabetic conditions promote binding of monocytes to vascular smooth muscle cells and their subsequent differentiation[J].Am J Physiol Heart Circ Physiol,2010,298(3):H736-H745.
[23]Donato R.RAGE:a single receptor for several ligands and different cellular responses:the case of certain S100 proteins[J].Curr Mol Med,2007,7(8):711-724.
[24]Lin J,Blake M,Tang C,et al.Inhibition of p53 transcriptional activity by the S100B calcium-binding protein[J].J Biol Chem,2001,276(37):35037-35041.
[25]Markowitz J,Chen I,Gitti R,et al.Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction[J].J Med Chem,2004,47(21):5085-5093.
[26]Lin J,Yang Q,Yan Z,et al.Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells[J].J Biol Chem,2004,279(32):34071-34077.
[27]Smith J,Stewart BJ,Glaysher S,et al.The effect of pentamidine on melanoma ex vivo[J].Anticancer Drugs,2010,21(2):181-185.
[28]Brozzi F,Arcuri C,Giambanco I,et al.S100B Protein Regulates Astrocyte Shape and Migration via Interaction with Src Kinase: IMPLICATIONS FOR ASTROCYTE DEVELOPMENT,ACTIVATION,AND TUMOR GROWTH[J].J Biol Chem,2009,284(13):8797-8811.
[29]Saito T,Ikeda T,Nakamura K,et al.S100A1 and S100B, transcriptional targets of SOX trio, inhibit terminal differentiation of chondrocytes[J].EMBO Rep,2007,8(5):504-509.
[30]Tubaro C,Arcuri C,Giambanco I,et al.S100B protein in myoblasts modulates myogenic differentiation via NF-kappaB-dependent inhibition of MyoD expression[J].J Cell Physiol,2010,223(1):270-282.
[31]Van Eldik LJ,Wainwright MS.The Janus face of glial-derived S100B:beneficial and detrimental functions in the brain[J].Restor Neurol Neurosci,2003,21(3-4):97-108.
[32]Huttunen HJ,Kuja-Panula J,Sorci G,et al.Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products(RAGE)activation[J].J Biol Chem,2000,275(51):40096-40105.
[33]Tsoporis JN,Izhar S,Proteau G,et al.S100B-RAGE dependent VEGF secretion by cardiac myocytes induces myofibroblast proliferation[J].J Mol Cell Cardiol,2012,52(2):464-473.
[34]Wei Q,Ren X,Jiang Y,et al.Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress[J].BMC Cardiovasc Disord,2013,13:13.

备注/Memo

备注/Memo:
收稿日期：2015-07-05.
通讯作者：王家宁，教授，主要从事血管重构研究Email:rywjn@vip.163.com
作者简介：杨波，教授，博士Email：yybb112@whu.edu.cn
更新日期/Last Update: 2016-07-10